Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genenta Science S.p.A. - American Depositary Shares (NQ: GNTA )

3.100 -0.010 (-0.32%)
Streaming Delayed Price Updated: 3:10 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,994
Open 3.120
Bid (Size) 1.250 (2)
Ask (Size) 3.170 (2)
Prev. Close 3.110
Today's Range 3.100 - 3.120
52wk Range 2.200 - 6.390
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
From GENENTA SCIENCE SPA
Via GlobeNewswire

Performance

YTD
-36.02%
-36.02%
1 Month
-6.63%
-6.63%
3 Month
-14.13%
-14.13%
6 Month
-36.02%
-36.02%
1 Year
-47.41%
-47.41%

More News

Read More
Genenta Science (NASDAQ: GNTA) Featured in Coverage of the 36th Annual Roth Conference
Via Investor Brand Network
This Small Cap Cancer Company 'Hijacks Tumors From Within," HC Wainwright Says
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
From GENENTA SCIENCE SPA
Via GlobeNewswire
Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Genenta to Present at Upcoming Scientific and Investor Conferences
From GENENTA SCIENCE SPA
Via GlobeNewswire
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments
From GENENTA SCIENCE SPA
Via GlobeNewswire
The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma
From GENENTA SCIENCE SPA
Via GlobeNewswire
Genenta to Provide Update on Lead Product Temferon™
From GENENTA SCIENCE SPA
Via GlobeNewswire
Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing
From GENENTA SCIENCE SPA
Via GlobeNewswire
Genenta Science (NASDAQ: GNTA) Featured in Coverage of the 35th Annual Roth Conference
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Genenta Sciences (NASDAQ: GNTA) Featured in Virtual Coverage of Roth’s Healthcare Opportunities Conference
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022
Via Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.